Zoetis Inc Total Assets
Zoetis Inc total assets. Based on the latest financial reports, Zoetis Inc (ZTS) holds total assets worth $15.16 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see cash flow conversion of Zoetis Inc for how efficiently the company converts equity into cash flow.
Total Assets of Zoetis Inc (2010–2024)
Total assets of Zoetis Inc from 2010 to 2024. This chart illustrates how Zoetis Inc's total assets have evolved over time, based on quarterly financial data. See Zoetis Inc (ZTS) stock price for real-time trading data and today's change.
Zoetis Inc - Asset Composition Analysis
Zoetis Inc Total Assets Breakdown (December 2024)
Zoetis Inc total assets breakdown as of December 2024. Zoetis Inc's total assets of $15.16 Billion consist of 42.1% current assets and 58.0% non-current assets. Explore how liquid is Zoetis Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $1.99 Billion | 13.9% |
| Accounts Receivable | $1.32 Billion | 9.2% |
| Inventory | $2.31 Billion | 16.2% |
| Property, Plant & Equipment | $3.62 Billion | 25.4% |
| Intangible Assets | $1.13 Billion | 7.9% |
| Goodwill | $2.72 Billion | 19.1% |
Asset Composition Trend (2010–2024)
This chart illustrates how Zoetis Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zoetis Inc's current assets represent 42.1% of total assets in 2024, an increase from 40.1% in 2010.
- Cash Position: Cash and equivalents constituted 13.9% of total assets in 2024, up from 1.2% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, a decrease from 34.0% in 2010.
- Asset Diversification: The largest asset category is property, plant & equipment at 25.4% of total assets.
Zoetis Inc Competitors by Total Assets
Key competitors of Zoetis Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
|
China | CN¥2.53 Billion |
|
Dezhan HealthCare Co Ltd
SHE:000813
|
China | CN¥4.77 Billion |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907
|
China | CN¥2.00 Billion |
Zoetis Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.64 | 3.69 | 3.05 |
| Quick Ratio | 2.28 | 2.27 | 2.30 |
| Cash Ratio | 0.00 | 1.00 | 0.00 |
| Working Capital | $4.78 Billion | $4.58 Billion | $4.44 Billion |
Zoetis Inc - Advanced Valuation Insights
This section examines the relationship between Zoetis Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.97 |
| Latest Market Cap to Assets Ratio | 2.44 |
| Asset Growth Rate (YoY) | -0.3% |
| Total Assets | $14.24 Billion |
| Market Capitalization | $34.73 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Zoetis Inc's assets at a significant premium (2.44x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Zoetis Inc's assets decreased by 0.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Zoetis Inc (2010–2024)
The table below shows the annual total assets of Zoetis Inc from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $14.24 Billion | -0.34% |
| 2023-12-31 | $14.29 Billion | -4.28% |
| 2022-12-31 | $14.93 Billion | +7.37% |
| 2021-12-31 | $13.90 Billion | +2.14% |
| 2020-12-31 | $13.61 Billion | +17.88% |
| 2019-12-31 | $11.54 Billion | +7.13% |
| 2018-12-31 | $10.78 Billion | +25.52% |
| 2017-12-31 | $8.59 Billion | +12.25% |
| 2016-12-31 | $7.65 Billion | -3.34% |
| 2015-12-31 | $7.91 Billion | +20.11% |
| 2014-12-31 | $6.59 Billion | +0.46% |
| 2013-12-31 | $6.56 Billion | +4.73% |
| 2012-12-31 | $6.26 Billion | +9.65% |
| 2011-12-31 | $5.71 Billion | +8.08% |
| 2010-12-31 | $5.28 Billion | -- |
About Zoetis Inc
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and… Read more